VEGFA and lung cancer: Three alternatives are currently available for the use of first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to treat EGFR-mutated lung cancer, such as single agents or combinatorial treatment with an anti-VEGF antibody or chemotherapy.